In summary, our results had shown that DARS/GDI2/P4HA2/TRUB1 can be used as a new biological marker for GBM, which is related to the occurrence and prognosis of GBM, how to rationally apply various genetic characteristics at specific stages of GBM for diagnose and prediction of prognosis. This evidence concerns the gene P4HA2 and glioblastoma.